Portage Biotech (PRTG) News Today → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free PRTG Stock Alerts $0.26 -0.02 (-7.11%) (As of 01:29 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | uk.investing.comPortage Biotech Inc (PRTG)April 14, 2024 | investing.comPortage Biotech halts trial enrollment, seeks strategic optionsApril 12, 2024 | msn.comPortage Down on Announcing AlternativesApril 12, 2024 | globenewswire.comPortage Biotech Announces Plans to Expand its Evaluation of Strategic AlternativesMarch 26, 2024 | globenewswire.comPortage Biotech Completes Monetization of Intensity Therapeutics (INTS) sharesMarch 11, 2024 | finance.yahoo.comPRTG: Extending the RunwayMarch 3, 2024 | morningstar.comPortage Biotech Inc PRTGFebruary 28, 2024 | globenewswire.comPortage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business UpdateJanuary 8, 2024 | realmoney.thestreet.comH.C. Wainwright downgrades Portage Biotech on financing overhangJanuary 8, 2024 | realmoney.thestreet.comPortage Biotech just downgraded at H.C. Wainwright, here's whyJanuary 8, 2024 | finance.yahoo.comPRTG: Bridging I-O: Working in Harmony with CheckpointsJanuary 4, 2024 | marketwatch.comPortage Biotech Shares Fall 6% on Job Reductions, Paused Drug Development ProgramJanuary 4, 2024 | markets.businessinsider.comPortage Biotech To Pause INKT Clinical Development; To Evaluate Potential Strategic OptionsJanuary 4, 2024 | msn.comPortage Biotech to halt iNKT drug program, cut workforceJanuary 4, 2024 | finance.yahoo.comPortage Biotech Reports Business and Strategic UpdateNovember 28, 2023 | msn.comPortage Biotech GAAP EPS of -$0.29November 28, 2023 | finance.yahoo.comPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business UpdateNovember 6, 2023 | benzinga.comPortage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comPortage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingOctober 31, 2023 | msn.comPortage Biotech files to sell 9.63M shares for holdersSeptember 29, 2023 | finance.yahoo.comPortage Biotech Announces $6.0 Million Registered Direct OfferingSeptember 20, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceSeptember 7, 2023 | markets.businessinsider.comAnalyst Expectations for Portage Biotech's FutureSeptember 5, 2023 | marketwatch.comPortage Biotech in Keytruda Collaboration With MerckSeptember 5, 2023 | finance.yahoo.comPortage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid TumorsSeptember 1, 2023 | msn.comCantor Fitzgerald Reiterates Portage Biotech (PRTG) Overweight RecommendationAugust 30, 2023 | finance.yahoo.comPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business UpdateAugust 2, 2023 | msn.comHC Wainwright & Co. Maintains Portage Biotech (PRTG) Buy RecommendationAugust 2, 2023 | markets.businessinsider.comPortage Biotech Inc (PRTG) Receives a Buy from H.C. WainwrightAugust 2, 2023 | health.usnews.comUniversity Hospitals Portage Medical CenterAugust 1, 2023 | msn.comCantor Fitzgerald Maintains Portage Biotech (PRTG) Overweight RecommendationJuly 31, 2023 | finance.yahoo.comPortage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business UpdateJune 26, 2023 | finance.yahoo.comPortage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid TumorsJune 5, 2023 | benzinga.comWhy Portage Biotech Stock Is Up TodayJune 5, 2023 | finance.yahoo.comPortage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual MeetingJune 5, 2023 | marketbeat.comTrading was temporarily halted for "PRTG" at 09:06 AM with a stated reason of "LULD pause."June 1, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion During the 2023 BIO International ConferenceApril 29, 2023 | usnews.comPortage Central High SchoolApril 26, 2023 | finance.yahoo.comPortage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 19, 2023 | usnews.comPortage High SchoolApril 12, 2023 | nytimes.comTrack Covid-19 in Portage County, WisconsinMarch 12, 2023 | benzinga.comPortage Biotech Stock (NASDAQ:PRTG), DividendsMarch 7, 2023 | finance.yahoo.comPortage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comPortage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022February 27, 2023 | finance.yahoo.comPortage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in CancerFebruary 23, 2023 | msn.comPortage Biotech reports FY resultsFebruary 15, 2023 | finance.yahoo.comPortage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership SummitJanuary 21, 2023 | seekingalpha.comPRTG Portage Biotech Inc.December 29, 2022 | marketbeat.comTrading was temporarily halted for "PRTG" at 10:12 AM with a stated reason of "LULD pause."December 5, 2022 | marketbeat.comQ3 2023 EPS Estimates for Portage Biotech Inc. (NASDAQ:PRTG) Raised by AnalystPortage Biotech Inc. (NASDAQ:PRTG - Get Rating) - Analysts at HC Wainwright lifted their Q3 2023 earnings per share (EPS) estimates for Portage Biotech in a note issued to investors on Thursday, December 1st. HC Wainwright analyst R. Burns now expects that the company will earn ($0.23) per share Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here PRTG Media Mentions By Week PRTG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTG News Sentiment▼0.230.44▲Average Medical News Sentiment PRTG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTG Articles This Week▼10▲PRTG Articles Average Week Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bright Minds Biosciences News Titan Medical News TFF Pharmaceuticals News NexImmune News TRACON Pharmaceuticals News TransCode Therapeutics News Artelo Biosciences News China Pharma News Kazia Therapeutics News Cingulate News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTG) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupBill Clinton Backing Biden Replacement???The Freeport SocietyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
